Costs of bleeds relating to acute coronary syndrome therapies

Alexander Bufe, Ferrari Emile, Laurent Drogoul, Josep Guindo Soldevila, Di Pasquale Giuseppe, Lettino Maddalena, Magnus Janzon, Ruth E. Brown

Research output: Contribution to journalArticle

Abstract

Objective: To estimate the costs to manage selected types of bleeding complications in patients with acute coronary syndrome (ACS) treated with antithrombotics, including antiplatelet, and fibrinolytic therapies: decrease in haemoglobin >3 g/dL, puncture site, and bleeding requiring transfusion of blood products. Methods: Retrospective chart reviews of ACS patients experiencing decrease in Hb, puncture site, or bleeding requiring transfusion were conducted in hospitals in France, Germany, Italy, Spain and Sweden to determine the total length of stay (LOS), stay post-bleeding, procedures to identify the extent of bleeding, number and types of transfusion products, patient demographics, reason for hospital admission and disposition upon discharge. Country-specific costs were applied to estimate the average cost per patient by type of bleeding event. Results: Records of 158 ACS patients with the bleeding complications were examined (26.9 decrease in Hb, 35.5 puncture site, and 37.8 transfusion). The average LOS was 10.6 days for decreasing Hb, 7.7 days for puncture site bleeding, and 11.3 days for patients receiving transfusions due to these bleeding events. The average costs per patient ranged between €3,986 and €10,252. The LOS ranged widely both within and across countries. Limitations: The study has a small sample size and costs are confounded by co-morbidities. Conclusions: The estimated costs for decreasing Hb, puncture site bleeding and bleeding resulting in transfusions provide a tool for researchers to conduct economic analyses of bleeding events associated with therapies for ACS.

Original languageEnglish
Pages (from-to)236-240
Number of pages5
JournalJournal of Medical Economics
Volume13
Issue number2
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Acute Coronary Syndrome
Hemorrhage
Costs and Cost Analysis
Punctures
Therapeutics
Length of Stay
Thrombolytic Therapy
Sweden
Blood Transfusion
Spain
Sample Size
Italy
France
Germany
Hemoglobins
Economics
Research Personnel
Demography
Morbidity

Keywords

  • Acute coronary syndrome
  • Bleeds
  • Costs

ASJC Scopus subject areas

  • Health Policy

Cite this

Bufe, A., Emile, F., Drogoul, L., Guindo Soldevila, J., Pasquale Giuseppe, D., Maddalena, L., ... Brown, R. E. (2010). Costs of bleeds relating to acute coronary syndrome therapies. Journal of Medical Economics, 13(2), 236-240. https://doi.org/10.3111/13696998.2010.488882

Costs of bleeds relating to acute coronary syndrome therapies. / Bufe, Alexander; Emile, Ferrari; Drogoul, Laurent; Guindo Soldevila, Josep; Pasquale Giuseppe, Di; Maddalena, Lettino; Janzon, Magnus; Brown, Ruth E.

In: Journal of Medical Economics, Vol. 13, No. 2, 06.2010, p. 236-240.

Research output: Contribution to journalArticle

Bufe, A, Emile, F, Drogoul, L, Guindo Soldevila, J, Pasquale Giuseppe, D, Maddalena, L, Janzon, M & Brown, RE 2010, 'Costs of bleeds relating to acute coronary syndrome therapies', Journal of Medical Economics, vol. 13, no. 2, pp. 236-240. https://doi.org/10.3111/13696998.2010.488882
Bufe A, Emile F, Drogoul L, Guindo Soldevila J, Pasquale Giuseppe D, Maddalena L et al. Costs of bleeds relating to acute coronary syndrome therapies. Journal of Medical Economics. 2010 Jun;13(2):236-240. https://doi.org/10.3111/13696998.2010.488882
Bufe, Alexander ; Emile, Ferrari ; Drogoul, Laurent ; Guindo Soldevila, Josep ; Pasquale Giuseppe, Di ; Maddalena, Lettino ; Janzon, Magnus ; Brown, Ruth E. / Costs of bleeds relating to acute coronary syndrome therapies. In: Journal of Medical Economics. 2010 ; Vol. 13, No. 2. pp. 236-240.
@article{7c5b37f459ba4627af854174cea772e0,
title = "Costs of bleeds relating to acute coronary syndrome therapies",
abstract = "Objective: To estimate the costs to manage selected types of bleeding complications in patients with acute coronary syndrome (ACS) treated with antithrombotics, including antiplatelet, and fibrinolytic therapies: decrease in haemoglobin >3 g/dL, puncture site, and bleeding requiring transfusion of blood products. Methods: Retrospective chart reviews of ACS patients experiencing decrease in Hb, puncture site, or bleeding requiring transfusion were conducted in hospitals in France, Germany, Italy, Spain and Sweden to determine the total length of stay (LOS), stay post-bleeding, procedures to identify the extent of bleeding, number and types of transfusion products, patient demographics, reason for hospital admission and disposition upon discharge. Country-specific costs were applied to estimate the average cost per patient by type of bleeding event. Results: Records of 158 ACS patients with the bleeding complications were examined (26.9 decrease in Hb, 35.5 puncture site, and 37.8 transfusion). The average LOS was 10.6 days for decreasing Hb, 7.7 days for puncture site bleeding, and 11.3 days for patients receiving transfusions due to these bleeding events. The average costs per patient ranged between €3,986 and €10,252. The LOS ranged widely both within and across countries. Limitations: The study has a small sample size and costs are confounded by co-morbidities. Conclusions: The estimated costs for decreasing Hb, puncture site bleeding and bleeding resulting in transfusions provide a tool for researchers to conduct economic analyses of bleeding events associated with therapies for ACS.",
keywords = "Acute coronary syndrome, Bleeds, Costs",
author = "Alexander Bufe and Ferrari Emile and Laurent Drogoul and {Guindo Soldevila}, Josep and {Pasquale Giuseppe}, Di and Lettino Maddalena and Magnus Janzon and Brown, {Ruth E.}",
year = "2010",
month = "6",
doi = "10.3111/13696998.2010.488882",
language = "English",
volume = "13",
pages = "236--240",
journal = "Journal of Medical Economics",
issn = "1369-6998",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Costs of bleeds relating to acute coronary syndrome therapies

AU - Bufe, Alexander

AU - Emile, Ferrari

AU - Drogoul, Laurent

AU - Guindo Soldevila, Josep

AU - Pasquale Giuseppe, Di

AU - Maddalena, Lettino

AU - Janzon, Magnus

AU - Brown, Ruth E.

PY - 2010/6

Y1 - 2010/6

N2 - Objective: To estimate the costs to manage selected types of bleeding complications in patients with acute coronary syndrome (ACS) treated with antithrombotics, including antiplatelet, and fibrinolytic therapies: decrease in haemoglobin >3 g/dL, puncture site, and bleeding requiring transfusion of blood products. Methods: Retrospective chart reviews of ACS patients experiencing decrease in Hb, puncture site, or bleeding requiring transfusion were conducted in hospitals in France, Germany, Italy, Spain and Sweden to determine the total length of stay (LOS), stay post-bleeding, procedures to identify the extent of bleeding, number and types of transfusion products, patient demographics, reason for hospital admission and disposition upon discharge. Country-specific costs were applied to estimate the average cost per patient by type of bleeding event. Results: Records of 158 ACS patients with the bleeding complications were examined (26.9 decrease in Hb, 35.5 puncture site, and 37.8 transfusion). The average LOS was 10.6 days for decreasing Hb, 7.7 days for puncture site bleeding, and 11.3 days for patients receiving transfusions due to these bleeding events. The average costs per patient ranged between €3,986 and €10,252. The LOS ranged widely both within and across countries. Limitations: The study has a small sample size and costs are confounded by co-morbidities. Conclusions: The estimated costs for decreasing Hb, puncture site bleeding and bleeding resulting in transfusions provide a tool for researchers to conduct economic analyses of bleeding events associated with therapies for ACS.

AB - Objective: To estimate the costs to manage selected types of bleeding complications in patients with acute coronary syndrome (ACS) treated with antithrombotics, including antiplatelet, and fibrinolytic therapies: decrease in haemoglobin >3 g/dL, puncture site, and bleeding requiring transfusion of blood products. Methods: Retrospective chart reviews of ACS patients experiencing decrease in Hb, puncture site, or bleeding requiring transfusion were conducted in hospitals in France, Germany, Italy, Spain and Sweden to determine the total length of stay (LOS), stay post-bleeding, procedures to identify the extent of bleeding, number and types of transfusion products, patient demographics, reason for hospital admission and disposition upon discharge. Country-specific costs were applied to estimate the average cost per patient by type of bleeding event. Results: Records of 158 ACS patients with the bleeding complications were examined (26.9 decrease in Hb, 35.5 puncture site, and 37.8 transfusion). The average LOS was 10.6 days for decreasing Hb, 7.7 days for puncture site bleeding, and 11.3 days for patients receiving transfusions due to these bleeding events. The average costs per patient ranged between €3,986 and €10,252. The LOS ranged widely both within and across countries. Limitations: The study has a small sample size and costs are confounded by co-morbidities. Conclusions: The estimated costs for decreasing Hb, puncture site bleeding and bleeding resulting in transfusions provide a tool for researchers to conduct economic analyses of bleeding events associated with therapies for ACS.

KW - Acute coronary syndrome

KW - Bleeds

KW - Costs

UR - http://www.scopus.com/inward/record.url?scp=77953349556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953349556&partnerID=8YFLogxK

U2 - 10.3111/13696998.2010.488882

DO - 10.3111/13696998.2010.488882

M3 - Article

C2 - 20465368

VL - 13

SP - 236

EP - 240

JO - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

IS - 2

ER -